Apimeds Pharmaceuticals US, Inc. (APUS) — Net Asset Momentum
Apimeds Pharmaceuticals US, Inc. (APUS) recorded a net asset momentum of -4361.3% as of December 2024, with net assets of $-1.36 Million USD. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Check APUS intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
YoY Momentum
Current Net Assets
Years of Data
Country
Apimeds Pharmaceuticals US, Inc. Net Asset Momentum (2021–2024)
This chart tracks Apimeds Pharmaceuticals US, Inc.'s year-over-year net asset growth across 4 annual reporting periods from 2021 to 2024. The most recent momentum reading is -4361.3%, with net assets of $-1.36 Million USD as of December 2024. Read Apimeds Pharmaceuticals US, Inc. (APUS) financial obligations for a breakdown of total debt and financial obligations.
Annual Net Asset History for Apimeds Pharmaceuticals US, Inc. (2021–2024)
The table below shows the complete annual net asset history for Apimeds Pharmaceuticals US, Inc. from 2021 to 2024, covering 4 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see market cap of Apimeds Pharmaceuticals US, Inc..
| Year | Net Assets (USD) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2024 | $-1.36 Million | $13.06K | $1.37 Million | ▼ -4361.3% |
| 2023 | $31.87K | $422.08K | $390.20K | ▲ +104.5% |
| 2022 | $-713.61K | $6.17K | $719.78K | ▼ -199.2% |
| 2021 | $-238.48K | $172.17K | $410.65K | — |